Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury

Heile, Anna; Wallrapp, Christine; Klinge, Petra M.; Samii, Amir; Kassem, Moustapha; Silverberg, Gerald D.; Brinker, Thomas

doi:10.1016/j.neulet.2009.07.071

Cited by 88 publications

(81 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This increases the geno-and phenotypic stability of the cells without affecting their differentiation potential [56]. In clinical trials, these cells were used for allogenic cell therapy approaches [57]. For the established process, the transfer to disposable is likely, as a geometric similar stirred system is available on the market (Mobius™ CellReady 3L bioreactor).…”

Section: Expansion Of Hmscs In Dynamic Systemsnew Conceptsmentioning

confidence: 99%

hMSC Production in Disposable Bioreactors with Regards to GMP and PAT

Cierpka

Elseberg

Niss³

et al. 2012

Chemie Ingenieur Technik

Self Cite

View full text Add to dashboard Cite

Reactor concepts for human mesenchymal stem cell (hMSC) production are introduced. Thereby, special interest is laid on the realization of these concepts as disposables fulfilling the GMP and PAT requirements. The specialty of the hMSC production process is the cell itself being the product. This results in completely different process requirements compared to e.g. protein production in mammalian cells. Thus, great attention has to be given to the shear sensitivity of the cells. The cultivation and the harvest of the cells have to be very gentle to neither influence cell viability nor cell differentiability. Further, the production process should not cause any undesirable cell changes. For hMSC production, cell harvest is the main challenging process step. The reactor concepts should be suitable for hMSC production for clinical trials as ATMPs. Therefore, disposable systems are especially applicable. The review describes more detailed bone marrow-derived hMSC production in a disposable stirred tank reactor as promising reactor concept.

show abstract

Section: Expansion Of Hmscs In Dynamic Systemsnew Conceptsmentioning

confidence: 99%

hMSC Production in Disposable Bioreactors with Regards to GMP and PAT

Cierpka

Elseberg

Niss³

et al. 2012

Chemie Ingenieur Technik

Self Cite

View full text Add to dashboard Cite

show abstract

“…stroke. Clinical phase 1 studies with 3 GLP-1-transfected cells revealed a reduced loss of neuronal cells in a controlled cortical impact rat model due to the implantation of GLP-1 secreting cell beads [8]. Originally, intestinal cells secret GLP-1in reply to food intake.…”

Section: Figurementioning

confidence: 99%

“…Therefore a maximal superficial velocity has to be defined, 8 in order to avoid negative effects on the cell growth caused by shear stress. Model parameters like growth and consumption rates, which are necessary for scale up calculations, were determined by fitting them to the experimental data.…”

Section: Reactor Systemmentioning

confidence: 99%

Production Process for Stem Cell Based Therapeutic Implants: Expansion of the Production Cell Line and Cultivation of Encapsulated Cells

Weber¹,

Pöhl²,

Poertner

et al. 2010

Bioreactor Systems for Tissue Engineering II

View full text Add to dashboard Cite

“…Human mesenchymal stem cells (hMSC) or allogenic stem-cell lines are a promising cell source for the manufacturing of cell therapeutic implants such as microencapsulated hMSC-TERT for the treatment of diabetes mellitus or stroke [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…In order to establish a practical relationship, the system was exemplarily scaled for the cultivation of 20 billion cells, which are sufficient for the production of about 200 single doses of CellBeads ® (CellMed AG, Alzenau, Germany). CellBeads ® are therapeutic implants, which are currently in a clinical phase II study for the treatment of stroke and consist of about 2000 to 2500 alginate encapsulated and genetically modified hMSC-TERT [1,4,6].…”

Section: Introductionmentioning

confidence: 99%

Expansion of Human Mesenchymal Stem Cells in a Fixed-Bed Bioreactor System Based on Non-Porous Glass Carrier – Part B: Modeling and Scale-up of the System

Weber¹,

Freimark²,

Pörtner

et al. 2010

Int J Artif Organs

Self Cite

View full text Add to dashboard Cite

Human mesenchymal stem cells (hMSC) are a promising cell source for the manufacturing of cell therapy or tissue-engineered implants. In part A of this publication a fixed-bed bioreactor system based on non-porous borosilicate glass spheres and procedures for the automated expansion of hMSC with high yield and vitality was introduced. Part B of this study deals with the modeling of the process in order to transfer the bioreactor system from the laboratory to the production scale. Relevant model parameters were obtained by fitting them to the experimental data of hMSC-TERT cultivations in scales up to 300 cm3. Scale-up calculations were carried out exemplarily for a target cell number of twenty billion cells.

show abstract

Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury

Cited by 88 publications

References 30 publications

hMSC Production in Disposable Bioreactors with Regards to GMP and PAT

hMSC Production in Disposable Bioreactors with Regards to GMP and PAT

Production Process for Stem Cell Based Therapeutic Implants: Expansion of the Production Cell Line and Cultivation of Encapsulated Cells

Expansion of Human Mesenchymal Stem Cells in a Fixed-Bed Bioreactor System Based on Non-Porous Glass Carrier – Part B: Modeling and Scale-up of the System

Contact Info

Product

Resources

About